Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bladder Cancer

Free Subscription 08.09.2025 1 Acad Radiol 1 Ann Med 1 Appl Immunohistochem Mol Morphol 1 Biomaterials 1 BJU Int 1 BMC Cancer 1 BMC Public Health 1 Can J Urol 2 Can Urol Assoc J 1 Cancer Heterog Plast 1 Cell Death Differ 1 Cell Signal 1 Chem Biodivers 1 Chem Biol Interact 2 Chirurgia (Bucur) 1 Clin Genitourin Cancer 1 Clin Nucl Med 1 Clin Transl Radiat Oncol 1 Curr Urol 1 Drug Dev Res 1 EJNMMI Radiopharm Chem 1 Eur J Nucl Med Mol Imaging 1 Eur Rev Med Pharmacol Sci 2 Expert Rev Anticancer Ther 1 Front Genet 1 Front Immunol 1 Front Oncol 1 Future Oncol 1 Genes Genomics 1 Health Inf Sci Syst 2 Hum Pathol 2 Int J Urol 2 Investig Clin Urol 1 J Exp Clin Cancer Res 1 J Robot Surg 1 Lancet Oncol 1 Minerva Urol Nephrol 1 Nanoscale 1 Oncogene 1 Pathol Res Pract 1 Pathology 1 PLoS One 1 Saudi Med J 2 Scand J Urol 1 Sci Rep 1 Talanta 1 Urol Case Rep 1 Urol Oncol 1 World J Clin Oncol 2 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acad Radiol

1. DU C, Wei W, Hu M, He J, et al
   Multi-DECT Image-based Interpretable Model Incorporating Habitat Radiomics and Vision Transformer Deep Learning for Preoperative Prediction of Muscle Invasion in Bladder Cancer.
   Acad Radiol. 2025 Aug 30:S1076-6332(25)00756-1. doi: 10.1016/j.acra.2025.
   PubMed         Abstract available
   
   

   
   Ann Med

2. TAN Z, Huang Y, Fu S, Li H, et al
   Construction of a gene-metabolite-microbiome regulatory network reveals novel therapeutic targets in bladder cancer through multi-omics analysis.
   Ann Med. 2025;57:2553220.
   PubMed         Abstract available
   
   

   
   Appl Immunohistochem Mol Morphol

3. INDULKAR S, Rao BV, Das D, Pasam MK, et al
   Deciphering the Molecular Landscape of Urothelial Carcinoma: Immunohistochemistry-based Subtyping Using 4 Easily Available Antibodies for Cost-effective Stratification.
   Appl Immunohistochem Mol Morphol. 2025;33:267-276.
   PubMed         Abstract available
   
   

   
   Biomaterials

4. GENG R, Shang H, Chen Z, Tang K, et al
   ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer.
   Biomaterials. 2025;326:123677.
   PubMed         Abstract available
   
   

   
   BJU Int

5. RUTTEN VC, Hesseling SAW, Franckena M, Zuiverloon TCM, et al
   Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancer.
   BJU Int. 2025 Sep 3. doi: 10.1111/bju.16876.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. LI C, Liu J, Wang L, Xiong W, et al
   Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression.
   BMC Cancer. 2025;25:1404.
   PubMed         Abstract available
   
   

   
   BMC Public Health

7. ERNST VS, Manz K, Weitmann K, Hoffmann W, et al
   Assessing cancer risk in firefighters in Northern Germany: a retrospective cohort study.
   BMC Public Health. 2025;25:2998.
   PubMed         Abstract available
   
   

   
   Can J Urol

8. CHAUMEL M, Brichart N, Bruyere F, Bourgi A, et al
   Impact of COVID-19 care reorganization on the prognosis of patients with bladder urothelial carcinoma: a multicentric retrospective study.
   Can J Urol. 2025;32:359-366.
   PubMed         Abstract available
   
   

   
   Can Urol Assoc J

9. KANAAN MF, Breau RH, Lavallee LT, McIsaac DI, et al
   Testosterone replacement therapy and bladder cancer.
   Can Urol Assoc J. 2025 Aug 28. doi: 10.5489/cuaj.9207.
   PubMed         Abstract available
   
   
10. ALIMOHAMED NS, Gotto G, Kulkarni GS, Black PC, et al
    A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada.
    Can Urol Assoc J. 2025 Aug 28. doi: 10.5489/cuaj.9111.
    PubMed         Abstract available
    
    

    
    Cancer Heterog Plast

11. XU D, Li Q
    Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer.
    Cancer Heterog Plast. 2025;2:10.
    PubMed         Abstract available
    
    

    
    Cell Death Differ

12. CHEN K, Chen J, Cong Y, He Q, et al
    Correction: TTK promotes mitophagy by regulating ULK1 phosphorylation and pre-mRNA splicing to inhibit mitochondrial apoptosis in bladder cancer.
    Cell Death Differ. 2025 Sep 1. doi: 10.1038/s41418-025-01571.
    PubMed        
    
    

    
    Cell Signal

13. WANG XL, Cao L, Wang YW, Chu T, et al
    Role of 3-mercaptopyruvate sulfurtransferase in cancer.
    Cell Signal. 2025;135:112020.
    PubMed         Abstract available
    
    

    
    Chem Biodivers

14. POOCHI SP, Sundarraj R, Raju MV, Kaniyur Chandrasekaran M, et al
    Harnessing Nature: Computational and Experimental Insights Into Ipomoea obscura Metabolites for Bladder Cancer Therapy.
    Chem Biodivers. 2025 Sep 2:e00909. doi: 10.1002/cbdv.202500909.
    PubMed         Abstract available
    
    

    
    Chem Biol Interact

15. CHANG KH, Chen HC, Chen CY, Tsai SP, et al
    Natural lignan justicidin A-induced mitophagy as a targetable niche in bladder cancer.
    Chem Biol Interact. 2025 Sep 3:111723. doi: 10.1016/j.cbi.2025.111723.
    PubMed         Abstract available
    
    

    
    Chirurgia (Bucur)

16. CHIUJDEA S, Petrut B, Martha O, Chiujdea AL, et al
    Prognostic Factors of Long-Term Survival in Non-Muscle-Invasive Bladder Cancer: An 18-Year Retrospective Study from Real-Life Practice.
    Chirurgia (Bucur). 2025;120:459-466.
    PubMed         Abstract available
    
    
17. RADU CG, Radavoi GD, Aurelian J, Achim IF, et al
    Bricker Urinary Diversion after Radical Cystectomy: A Comparative Analysis of Laparoscopic vs. Robotic Approach in Terms of Quality of Life, Perioperative Outcomes and Postoperative Complications.
    Chirurgia (Bucur). 2025;120:446-458.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

18. HU L, Hu JW, Wang CQ, Li RY, et al
    Neoadjuvant PD-1/PD-L1 Inhibitors for Muscle-Invasive Bladder Cancer: A Meta-Analysis.
    Clin Genitourin Cancer. 2025;23:102408.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

19. SABER TANHA A, Raeisi N, Jafari Zarrin Ghabaei F, Aryana K, et al
    Comparable Diagnostic Performance of 99m Tc-FAPI Scintigraphy and Contrast-enhanced CT in Restaging a Rare Case of Metastatic Colon Adenocarcinoma to the Urachus.
    Clin Nucl Med. 2025;50:e626-e627.
    PubMed         Abstract available
    
    

    
    Clin Transl Radiat Oncol

20. MOSE L, Maitre P, Eberz P, Zilli T, et al
    Treatment approaches for non-metastatic small cell bladder cancer: a meta-analysis of reconstructed Kaplan-Meier curves.
    Clin Transl Radiat Oncol. 2025;55:101032.
    PubMed         Abstract available
    
    

    
    Curr Urol

21. SHI M, Meng X, Xu X, Wang Q, et al
    Gene and pathway analysis of genome-wide genetic associations of bladder cancer.
    Curr Urol. 2025;19:321-330.
    PubMed         Abstract available
    
    

    
    Drug Dev Res

22. WANG B, Wu K, Cui Y, Han X, et al
    Effects of a Dendritic Cell Vaccine Loaded With Whole Tumor Antigen on Bladder Cancer Model in hu-PBL-SCID Mice.
    Drug Dev Res. 2025;86:e70157.
    PubMed         Abstract available
    
    

    
    EJNMMI Radiopharm Chem

23. LINDLAND K, Juzeniene A
    Cytotoxicity of (212)Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.
    EJNMMI Radiopharm Chem. 2025;10:58.
    PubMed         Abstract available
    
    

    
    Eur J Nucl Med Mol Imaging

24. UNTERRAINER LM, Schmid HP, Kunte SC, Holzgreve A, et al
    (68)Ga-FAPI and (18)F-FAPI PET/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients.
    Eur J Nucl Med Mol Imaging. 2025;52:3963-3974.
    PubMed         Abstract available
    
    

    
    Eur Rev Med Pharmacol Sci

25. BIGLIA A, Sacchi MC, Maggiore F, Morandi V, et al
    Case report: atypical anti-SAE1 autoantibody manifestation with splinter hemorrhages as onset, and related to urothelial cancer.
    Eur Rev Med Pharmacol Sci. 2025;29:398-403.
    PubMed         Abstract available
    
    

    
    Expert Rev Anticancer Ther

26. AMINSHARIFI A, Saran Manivasagam S, Askarpour MR, Raman JD, et al
    Is organ preserving radical cystectomy in women oncologically safe and does it improve quality of life?
    Expert Rev Anticancer Ther. 2025;25:1075-1085.
    PubMed         Abstract available
    
    
27. AN W, Shen D, Li D, Shen J, et al
    Unmasking disparities in bladder cancer outcomes in the disaggregated Asian American population.
    Expert Rev Anticancer Ther. 2025 Sep 3:1-10. doi: 10.1080/14737140.2025.2556884.
    PubMed         Abstract available
    
    

    
    Front Genet

28. WANG T, Ding F, Sun K
    Construction and immunohistochemical validation of a necroptosis-related prognostic signature in bladder cancer and its association with tumor immune infiltration.
    Front Genet. 2025;16:1527907.
    PubMed         Abstract available
    
    

    
    Front Immunol

29. MENG L, Zhu X, Ji X, Wang B, et al
    Advances in the immunological microenvironment and immunotherapy of bladder cancer.
    Front Immunol. 2025;16:1609871.
    PubMed         Abstract available
    
    

    
    Front Oncol

30. SO SW, Han JH, Yuk HD, Jeong CW, et al
    High carbohydrate antigen 19-9 levels indicate poor prognosis in patients with bladder cancer following radical cystectomy.
    Front Oncol. 2025;15:1550203.
    PubMed         Abstract available
    
    

    
    Future Oncol

31. POWLES TB, Grande E, Alimohamed N, Oliveira N, et al
    SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.
    Future Oncol. 2025;21:2705-2712.
    PubMed         Abstract available
    
    

    
    Genes Genomics

32. JEONG IS, Seo JW, Park SJ, Kim SY, et al
    Deep learning-driven whole-slide image analysis predicts chemo-resistance and motility subtypes in muscle-invasive bladder cancer.
    Genes Genomics. 2025 Sep 4. doi: 10.1007/s13258-025-01677.
    PubMed         Abstract available
    
    

    
    Health Inf Sci Syst

33. DING Y, Pan Y, Geyer CR, Vizeacoumar FJ, et al
    Unraveling bladder cancer-related circRNA biomarkers: a hybrid model combining deep learning and statistics.
    Health Inf Sci Syst. 2025;13:53.
    PubMed         Abstract available
    
    

    
    Hum Pathol

34. MI W, Zang C, Zhao J, Kamat AM, et al
    Mixed-grade papillary urothelial carcinoma with a minor high-grade component shows a significantly worse clinical outcome than low-grade papillary urothelial carcinoma.
    Hum Pathol. 2025;163:105904.
    PubMed         Abstract available
    
    
35. CHAN E, Stohr BA, Sangoi AR, Sirohi D, et al
    Invasive urothelial carcinoma with chordoid and myxoid features shows increased RAS/RAF pathway alterations.
    Hum Pathol. 2025;163:105882.
    PubMed         Abstract available
    
    

    
    Int J Urol

36. URABE F, Tashiro K, Imai Y, Iwatani K, et al
    Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative Study.
    Int J Urol. 2025;32:1147-1156.
    PubMed         Abstract available
    
    
37. TILLU N, Dovey Z, Choudhary M, Venkatesh A, et al
    Open Versus Robotic Radical Cystectomy With Intracorporeal Neobladder: A Decade-Long Single-Surgeon Experience.
    Int J Urol. 2025;32:1234-1242.
    PubMed         Abstract available
    
    

    
    Investig Clin Urol

38. OH JJ, Hong SK
    Contemporary management of metastatic urothelial carcinoma.
    Investig Clin Urol. 2025;66:375-382.
    PubMed         Abstract available
    
    
39. PARK JH, Lee S, Jeong SH, Ku JH, et al
    The effect of neoadjuvant chemotherapy on survival outcomes subsequent to radical cystectomy in pathological T0 bladder cancer patients: A multicenter large-scale analysis.
    Investig Clin Urol. 2025;66:395-404.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

40. LI T, Zhu K, Tong H, Sun Y, et al
    Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by enhancing nucleotide excision repair in bladder cancer.
    J Exp Clin Cancer Res. 2025;44:265.
    PubMed         Abstract available
    
    

    
    J Robot Surg

41. MISRA S, Bisht R, Motiwala ZY, Puniyani A, et al
    Is it prime time for stent-less robotic radical cystectomy? A scoping review.
    J Robot Surg. 2025;19:560.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

42. NECCHI A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, et al
    TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open
    Lancet Oncol. 2025 Aug 27:S1470-2045(25)00358.
    PubMed         Abstract available
    
    

    
    Minerva Urol Nephrol

43. SORIA F, Mari A, Moschini M, Naspro R, et al
    The current role of photodynamic diagnosis (PDD) in the management of non-muscle invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper.
    Minerva Urol Nephrol. 2025;77:443-450.
    PubMed         Abstract available
    
    

    
    Nanoscale

44. CHUANG AE, Tao YK, Fan YJ, Chiu HJ, et al
    Synergistic nanoplatform of M1 macrophage-derived extracellular vesicles and MoS(2) for tumor-targeted photoimmunotherapy in bladder cancer.
    Nanoscale. 2025 Sep 3. doi: 10.1039/d5nr00374.
    PubMed         Abstract available
    
    

    
    Oncogene

45. WANG Y, Jerome NA, Kelleher AJ, Henderson ML, et al
    TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion.
    Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03557.
    PubMed         Abstract available
    
    

    
    Pathol Res Pract

46. DEYHIMFAR R, Gholami K, Oskouie IM, Baghdadabad LZ, et al
    High-dose vitamin C improves BCG immunotherapy's efficacy in a murine ectopic model of bladder cancer.
    Pathol Res Pract. 2025;275:156207.
    PubMed         Abstract available
    
    

    
    Pathology

47. DELAHUNT B, Johannsen S, Egevad L, Yaxley JW, et al
    High proportion of clinically significant prostate adenocarcinomas in radical cystoprostatectomy specimens following complete prostate sampling.
    Pathology. 2025;57:708-711.
    PubMed         Abstract available
    
    

    
    PLoS One

48. HSIEH KL, Huang KH, Chang CP, Tsai HW, et al
    CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.
    PLoS One. 2025;20:e0331289.
    PubMed         Abstract available
    
    

    
    Saudi Med J

49. SAHARTI SN, Almutairi FM
    Trends in genitourinary tumors: Academic center experience over 16 years.
    Saudi Med J. 2025;46:985-991.
    PubMed         Abstract available
    
    

    
    Scand J Urol

50. MALMSTROM PU, Wang EYH
    Paradigm shift in the treatment of bladder cancer? The Swedish perspective.
    Scand J Urol. 2025;60:186-188.
    PubMed         Abstract available
    
    
51. LIEDBERG F, Baseckas G, Blackberg M, Fridriksdottir R, et al
    Survival patterns after perioperative treatment escalation and cystectomy for synchronous oligometastatic bladder cancer (M1a/M1b) - a population-based series.
    Scand J Urol. 2025;60:173-179.
    PubMed         Abstract available
    
    

    
    Sci Rep

52. ZHAO L, Xu Z, Ren L, Zheng S, et al
    Investigating the relationship between peripheral blood transferrin receptor protein and tumor cell ferroptosis, invasion, and metastasis in bladder cancer.
    Sci Rep. 2025;15:32197.
    PubMed         Abstract available
    
    

    
    Talanta

53. CARAPITO A, Fernandes Ferreira VS, Silva Ferreira AC, Teixeira-Marques A, et al
    Non-invasive bladder cancer detection: Identification of a urinary volatile biomarker panel using GC-MS metabolomics and machine learning.
    Talanta. 2025;297.
    PubMed         Abstract available
    
    

    
    Urol Case Rep

54. GONZALEZ V, Linton E, Boyce T, Dahmoush L, et al
    Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer.
    Urol Case Rep. 2025;62:103165.
    PubMed         Abstract available
    
    

    
    Urol Oncol

55. BAKALOUDI DR, Koehne EL, Voutsinas JM, Diamantopoulos LNu, et al
    Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study.
    Urol Oncol. 2025 Sep 2:S1078-1439(25)00282-0. doi: 10.1016/j.urolonc.2025.
    PubMed         Abstract available
    
    

    
    World J Clin Oncol

56. MAURYA N, Singh R, Goel A, Singhai A, et al
    Correction to "Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3beta/ beta-catenin in urinary bladder cancer patients".
    World J Clin Oncol. 2025;16:107778.
    PubMed         Abstract available
    
    

    
    World J Urol

57. RINGIA JB, Scholte FEF, Lijnen RAG, Algie E, et al
    Routine annual imaging does not aid in diagnosing new functional complications more than five years after RC with ileal conduit.
    World J Urol. 2025;43:539.
    PubMed         Abstract available
    
    
58. SHI Z, Luo Z, Luo W, Zhao B, et al
    Letter to the editor: "bladder cancer isn't BPH: why TURBT patients deserve separate risk models for complicated UTI".
    World J Urol. 2025;43:527.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.